<DOC>
	<DOCNO>NCT01915134</DOCNO>
	<brief_summary>The investigator design study evaluate efficiency acute toxicity recombinant human endostatin ( endostar ) combine chemotherapy metastatic nasopharyngeal carcinoma ( NPC ) .</brief_summary>
	<brief_title>Endostatin Combination With Chemotherapy Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>To evaluate progression free survival ( PFS ) , overall survival ( OS ) , Acute adverse reaction recombinant human endostatin ( endostar ) combine chemotherapy metastatic nasopharyngeal carcinoma ( NPC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>metastatic nasopharyngeal carcinoma 6 month first treatment , never receive anticancer treatment except local radiotherapy bone metastasis，at least one measurable metastatic lesions，ECOG PS 01，Electrocardiogram ( ecg ) special abnormal，comply test requirement , cooperate regular followup . To give local treatment , clinical severe infection ( &gt; grade 2 ) , central nervous system metastasis , ECOG PS≥2 , patient pregnancy breastfeeding , history peripheral nerve disease , concomitant serious disease , ever concomitant serious disease except Cervical carcinoma situ , cure basal cell carcinoma , bladder surface tumor , cancer 3 year curation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>Recombinant Human Endostatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>gemcitabine cisplatin</keyword>
</DOC>